Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-74788 Phase 2 in Adult CAH
NCT03525886Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crinecerfont in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Started Apr 2018; status: completed.
02
Drugs
crinecerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03525886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525886.